Xenon Pharmaceuticals Inc Positive Topline Results from Phase 2b 'X-TOLE' Clinical Trial of XEN1101 Call Transcript
Hello, and welcome to the Xenon Pharmaceuticals announces topline results from X-TOLE clinical trial conference call. (Operator Instructions) As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Sherry Aulin, Xenon's Chief Financial Officer.
Good morning. My name is Sherry Aulin, and I'm Xenon's Chief Financial Officer, and I will be moderating the call this morning. Thank you for joining us on our call and webcast to discuss our topline results from the Phase IIb actual clinical trial of XEN1101 for the treatment of focal epilepsy.
Joining me on today's call are Ian Mortimer, Xenon's President and Chief Executive Officer; Dr. Chris Kenney, Xenon's Chief Medical Officer; and Chris Von Seggern, Xenon's Chief Commercial Officer. For those of you on the webinar, there are slides accompanying this commentary from the executive team. At the end of the prepared remarks, we will open up the telephone lines for question-and-answer session.
Please be advised that during this call, we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
